Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis
Andreas Wollenberg, Jonathan I. Silverberg, Franz J. Legat, Marie Tauber, Vivian T. Laquer, April W. Armstrong, Andrew E. Pink, Luigi Naldi, Grażyna Pulka, Jacek Zdybski, Athanasios Tsianakas, Jorge Diaz, Inese Svarca, Jennifer Beecker, Galina Balakirski, Sylvia Pauser, Liliana Ulianov, Anna Ryzhkova, Jean-Loup Machu, Christophe Piketty · 2026
Read Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis by Andreas Wollenberg, Jonathan I. Silverberg, Franz J. Legat, Marie Tauber, Vivian T. Laquer, April W. Armstrong, Andrew E. Pink, Luigi Naldi, Grażyna Pulka, Jacek Zdybski, Athanasios Tsianakas, Jorge Diaz, Inese Svarca, Jennifer Beecker, Galina Balakirski, Sylvia Pauser, Liliana Ulianov, Anna Ryzhkova, Jean-Loup Machu, Christophe Piketty (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13253760.txt.
Description
Andreas Wollenberg leads a 2026 report on nemolizumab for moderate to severe atopic dermatitis, a long-term itchy skin disease. Two global phase 3 trials, ARCADIA 1 and 2, first treated teens and adults for 16 weeks. Then 507 patients who had responded were split to keep the drug every 4 or 8 weeks, or stop it.
By week 48, clear or near-clear skin held in 61.5% on the 4-week plan and 60.4% on the 8-week plan, versus 49.7% after stopping. A 75% gain in a skin score held in about 76% in both drug groups. Side effect rates were alike across groups.
Catalog record
| CREATOR | Andreas Wollenberg, Jonathan I. Silverberg, Franz J. Legat, Marie Tauber, Vivian T. Laquer, April W. Armstrong, Andrew E. Pink, Luigi Naldi, Grażyna Pulka, Jacek Zdybski, Athanasios Tsianakas, Jorge Diaz, Inese Svarca, Jennifer Beecker, Galina Balakirski, Sylvia Pauser, Liliana Ulianov, Anna Ryzhkova, Jean-Loup Machu, Christophe Piketty |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34386 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |